# Denali Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/denali-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.denalitherapeutics.com
- Total disclosed funding: $349M
- Latest round: Series B (Aug 25, 2016)
- Investors on record: 5

## About

Denali Therapeutics Inc. is dedicated to discovering and developing innovative therapeutics aimed at treating neurodegenerative and lysosomal storage diseases, notably focusing on conditions such as Alzheimer’s and Parkinson’s.Founded in 2015, Denali Therapeutics Inc. is based in San Francisco, US, and specializes in developing treatments for neurodegenerative diseases. The company, led by CEO Ryan Watts, has raised a total of USD 275.00 mn, primarily through a recent Private Placement/Follow on in October 2022. Denali has executed 6 deals to date, with its most recent deal occurring on October 19, 2022.Denali Therapeutics focuses on the discovery and development of innovative therapeutics targeting neurodegenerative and lysosomal storage diseases. Their core offerings include advanced drug candidates designed to address critical pathways involved in diseases such as Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS), and Hunter Syndrome. Denali's flagship product, DNL310, employs a novel transport vehicle technology aimed at improving the delivery of therapeutics across the blood-brain barrier, a significant challenge in treating neurological disorders. The end-users of these therapeutics are primarily patients suffering from these debilitating conditions, and the company actively partners with healthcare providers and research institutions to facilitate treatment access. Denali’s products are targeted at markets in North America, Europe, and select countries in Asia, where there is a high prevalence of neurodegenerative diseases and a considerable demand for effective treatments.In 2023, Denali Therapeutics reported revenue of USD 330.53 mn with an EBITDA of USD -479.55 mn. The company generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions that facilitate the development and commercialization of its therapeutics. Revenue streams are primarily derived from milestone payments associated with the progression of clinical trials, as well as potential royalties from future sales of successfully commercialized products.Denali Therapeutics aims to enhance its product offerings with new therapeutics targeting neurodegenerative diseases, leveraging funding from its most recent USD 275 mn Private Placement in October 2022 to support these initiatives. The company is also looking to expand its reach into additional markets, focusing on North America, Europe, and targeted regions in Asia by 2024. Denali’s strategies include developing innovative solutions to improve patient outcomes and addressing the significant unmet clinical needs in neurodegenerative diseases.

## Funding rounds

- Series B, Aug 25, 2016, $8M — Baillie Gifford
- Series B, Jun 5, 2016, $124M — ARCH Venture Partners, Flagship Pioneering, Alaska Permanent Fund Corporation, F-Prime Capital, Baillie Gifford
- Series A, May 14, 2015, $217M — ARCH Venture Partners, Flagship Pioneering, Alaska Permanent Fund Corporation, F-Prime Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B
- Alaska Permanent Fund Corporation — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series B